Nuvaring (Ethinylestradiol, Etonogestrel)

Nuvaring is a combined hormonal contraceptive that works within the reproductive hormone pathway to prevent ovulation.

• Contraception: Provides effective, reversible birth control for up to three months per ring.
• Menstrual cycle regulation: Helps synchronize menstrual bleeding and reduce irregular bleeding episodes.
• Endometriosis symptom relief: May lessen pelvic pain associated with endometriolysis.
• Acne management: Offers hormonal regulation that can improve skin clarity in some women.

• Nuvaring releases a steady low dose of ethinylestradiol and etonogestrel through the vaginal mucosa, providing systemic estrogen and progestogen levels that suppress the hypothalamic‑pituitary‑ovarian axis. This inhibition prevents the mid‑cycle luteinizing hormone surge, thereby blocking follicular development and ovulation.

Side effects vary in frequency and severity.

Common Side Effects

• Vaginal irritation or discharge: mild irritation or increased discharge at the application site.
• Headache: tension‑type or mild migraine‑type headaches.
• Nausea: occasional mild nausea, especially when first using the ring.
• Breast tenderness: mild swelling or tenderness of the breast tissue.
• Mood changes: mild fluctuations in mood or emotional state.

Serious or Rare Side Effects

• Deep vein thrombosis: blood clot formation in the deep veins, potentially life‑threatening.
• Pulmonary embolism: clot migration to the lungs causing respiratory distress.
• Stroke: cerebrovascular event presenting with sudden neurological deficits.
• Hepatic adenoma: benign liver tumor associated with prolonged estrogen exposure.
• Severe allergic reaction: anaphylaxis or angioedema requiring immediate medical care.

When prescribing Nuvaring, clinicians should consider several safety aspects.

• Contraindications: women with a history of thromboembolic disorders, estrogen‑dependent tumors, or active liver disease should not use this product.
• Smoking: patients who smoke and are over 35 years old should avoid use due to increased cardiovascular risk.
• Cardiovascular risk: assess blood pressure and lipid profile before initiating therapy.
• Medication review: evaluate concurrent use of enzyme‑inducing drugs that may reduce contraceptive efficacy.
• Follow‑up: schedule regular follow‑up visits to monitor for adverse events and correct use.

Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Nuvaring may interact with other medicines that influence hormone metabolism or clotting pathways.

Major Interactions (Avoid)

• Antiepileptic enzymes inducers (e.g., carbamazepine, phenytoin): may markedly reduce contraceptive effectiveness.
• Rifampicin: strong inducer that can lead to contraceptive failure.
• Certain antivirals (e.g., ritonavir): may lower hormone levels and compromise efficacy.

Moderate Interactions (Monitor Closely)

• Antifungal azoles (ketoconazole, itraconazole): may increase hormone concentrations and risk of side effects.
• St. John’s wort: can modestly reduce hormone levels, requiring counseling.
• Antibiotics (broad‑spectrum): may alter gut flora and slightly affect hormone re‑absorption, though clinical impact is limited.